ANDA 202743, held by Padagis Israel. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 202743 (Azelastine Hydrochloride), held by Padagis Israel, was first approved by FDA on May 8, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 8, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.2055MG/SPRAY · spray, metered;nasal | Azelastine Hydrochloride | Discontinued |
| Nov 13, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 8, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters